CN100537534C - 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途 - Google Patents

芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途 Download PDF

Info

Publication number
CN100537534C
CN100537534C CNB2005800050936A CN200580005093A CN100537534C CN 100537534 C CN100537534 C CN 100537534C CN B2005800050936 A CNB2005800050936 A CN B2005800050936A CN 200580005093 A CN200580005093 A CN 200580005093A CN 100537534 C CN100537534 C CN 100537534C
Authority
CN
China
Prior art keywords
group
formula
phenyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005800050936A
Other languages
English (en)
Chinese (zh)
Other versions
CN1922138A (zh
Inventor
A·阿布亚布德拉
A·阿尔马里奥加西亚
J·弗鲁瓦桑
C·霍尔奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN1922138A publication Critical patent/CN1922138A/zh
Application granted granted Critical
Publication of CN100537534C publication Critical patent/CN100537534C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
CNB2005800050936A 2004-01-16 2005-01-07 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途 Expired - Fee Related CN100537534C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400389A FR2865205B1 (fr) 2004-01-16 2004-01-16 Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR0400389 2004-01-16

Publications (2)

Publication Number Publication Date
CN1922138A CN1922138A (zh) 2007-02-28
CN100537534C true CN100537534C (zh) 2009-09-09

Family

ID=34707893

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005800050936A Expired - Fee Related CN100537534C (zh) 2004-01-16 2005-01-07 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途

Country Status (28)

Country Link
US (3) US7439257B2 (enExample)
EP (1) EP1708994B1 (enExample)
JP (1) JP4705590B2 (enExample)
KR (1) KR101171462B1 (enExample)
CN (1) CN100537534C (enExample)
AR (1) AR047384A1 (enExample)
AT (1) ATE369336T1 (enExample)
AU (1) AU2005212868B2 (enExample)
BR (1) BRPI0506918A (enExample)
CA (1) CA2552565C (enExample)
CY (1) CY1106918T1 (enExample)
DE (1) DE602005001930T2 (enExample)
DK (1) DK1708994T3 (enExample)
ES (1) ES2289701T3 (enExample)
FR (1) FR2865205B1 (enExample)
HR (1) HRP20070421T3 (enExample)
IL (1) IL176769A (enExample)
MA (1) MA28343A1 (enExample)
ME (1) MEP26408A (enExample)
NO (1) NO20063681L (enExample)
NZ (1) NZ548530A (enExample)
PL (1) PL1708994T3 (enExample)
PT (1) PT1708994E (enExample)
RS (1) RS50518B (enExample)
RU (1) RU2392269C2 (enExample)
TW (1) TWI402067B (enExample)
WO (1) WO2005077898A1 (enExample)
ZA (1) ZA200605698B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) * 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
EP2607362B1 (en) 2005-02-17 2014-12-31 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
US8197472B2 (en) 2005-03-25 2012-06-12 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US7918848B2 (en) 2005-03-25 2011-04-05 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2008023720A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
EP2094683B1 (en) * 2006-12-06 2011-10-12 GlaxoSmithKline LLC Bicyclic compounds and use as antidiabetics
CL2008002384A1 (es) * 2007-08-15 2009-07-17 Glaxo Group Ltd Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
JP2011500634A (ja) * 2007-10-16 2011-01-06 グラクソ グループ リミテッド 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体
US9968396B2 (en) 2008-05-27 2018-05-15 Maquet Cardiovascular Llc Surgical instrument and method
US9402679B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovascular Llc Surgical instrument and method
US9402680B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovasular, Llc Surgical instrument and method
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
US9955858B2 (en) * 2009-08-21 2018-05-01 Maquet Cardiovascular Llc Surgical instrument and method for use
RU2012135525A (ru) * 2010-01-20 2014-02-27 Санофи Производные алкилгетероциклических карбаматов, их получение и применение в терапии

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087569A1 (en) 2001-04-27 2002-11-07 Bristol-Myers Squibb Company Bisarylimidazolyl fatty acid amide hydrolase inhibitors
WO2003065989A2 (en) * 2002-02-08 2003-08-14 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
WO2004067498A2 (fr) 2003-01-23 2004-08-12 Sanofi-Aventis Derives d’ arylalkylcarbamates, leur preparation et leur application en therapeutique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605793A5 (fr) * 1974-03-05 1978-10-13 Soc Et Scient Et Ind Procédé de préparation de nouveaux N-(1benzylpyrrollidinil 2-alkyl) benzamides substitués
CA2308850C (en) * 1997-11-24 2007-07-10 The Scripps Research Institute Inhibitors of gap junction communication
JP4949552B2 (ja) 1998-04-16 2012-06-13 エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド インテグリンのそれの受容体への結合を阻害するｎ，ｎ−ジ置換アミド
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
CN100408556C (zh) * 2002-10-07 2008-08-06 加利福尼亚大学董事会 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
US7662971B2 (en) * 2002-10-08 2010-02-16 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087569A1 (en) 2001-04-27 2002-11-07 Bristol-Myers Squibb Company Bisarylimidazolyl fatty acid amide hydrolase inhibitors
WO2003065989A2 (en) * 2002-02-08 2003-08-14 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
WO2004067498A2 (fr) 2003-01-23 2004-08-12 Sanofi-Aventis Derives d’ arylalkylcarbamates, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design, synthesis, and structure-activity relationships ofalkylcarbamic acid aryl esters, a new class of fatty acid amidehydrolase inhibitors.. TARZIA G et al.Journal of Medicinal Chemistry,Vol.46 No.12. 2003

Also Published As

Publication number Publication date
IL176769A (en) 2010-06-30
ZA200605698B (en) 2007-11-28
DE602005001930D1 (de) 2007-09-20
TWI402067B (zh) 2013-07-21
BRPI0506918A (pt) 2007-06-05
FR2865205A1 (fr) 2005-07-22
US20100120845A1 (en) 2010-05-13
WO2005077898A1 (fr) 2005-08-25
US7439257B2 (en) 2008-10-21
US20080312262A1 (en) 2008-12-18
DK1708994T3 (da) 2007-11-26
AR047384A1 (es) 2006-01-18
US20070021424A1 (en) 2007-01-25
CN1922138A (zh) 2007-02-28
CA2552565C (fr) 2013-12-31
KR20070000478A (ko) 2007-01-02
US8026258B2 (en) 2011-09-27
HK1101283A1 (zh) 2007-10-12
JP2007522111A (ja) 2007-08-09
EP1708994B1 (fr) 2007-08-08
CA2552565A1 (fr) 2005-08-25
MEP26408A (en) 2010-06-10
RU2006129640A (ru) 2008-02-27
TW200536524A (en) 2005-11-16
DE602005001930T2 (de) 2008-04-30
AU2005212868A1 (en) 2005-08-25
JP4705590B2 (ja) 2011-06-22
HRP20070421T3 (hr) 2007-10-31
EP1708994A1 (fr) 2006-10-11
RU2392269C2 (ru) 2010-06-20
CY1106918T1 (el) 2012-09-26
US7674805B2 (en) 2010-03-09
ATE369336T1 (de) 2007-08-15
NZ548530A (en) 2010-02-26
IL176769A0 (en) 2006-10-31
PT1708994E (pt) 2007-10-02
ES2289701T3 (es) 2008-02-01
RS50518B (sr) 2010-05-07
AU2005212868B2 (en) 2011-04-21
MA28343A1 (fr) 2006-12-01
KR101171462B1 (ko) 2012-08-07
NO20063681L (no) 2006-09-18
FR2865205B1 (fr) 2006-02-24
PL1708994T3 (pl) 2008-01-31

Similar Documents

Publication Publication Date Title
CN100537534C (zh) 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途
CN106349156B (zh) 可用作cb2激动剂的吡啶-2-酰胺类
CN112839942B (zh) 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
TW201106863A (en) Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
CN100567279C (zh) 烷基哌嗪-和烷基高哌嗪-羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CA2542373A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
CA2542370A1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
HU230422B1 (hu) N-(1-acetilpiperidin-4-il)-4-fluor-benzamid és az azt tartalmazó gyógyszerészeti készítmények
WO2020063824A1 (zh) 硝羟喹啉前药及其用途
CA2731789A1 (fr) Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique
FR2928149A1 (fr) Composes derives d'azetidines, leur preparation et leur application en therapeutique
SK7522003A3 (en) Biphenylcarboxamides useful as lipid lowering agents
TWI501953B (zh) 環己烷衍生物化合物
CA2663080A1 (fr) Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique.
EP2324015B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
CN1926097B (zh) 杂芳基-烷基氨基甲酸酯的衍生物、其制备方法和作为faah酶抑制剂的用途
CN101374811A (zh) 新型双重nk2/nk3-拮抗剂、含它们的药物组合物、及其制备方法
EP1899298A2 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
CA2729896A1 (fr) Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
JP2006514617A (ja) 疼痛または胃腸障害の治療のためのフェニル−ピペリジン−４−イリデン−メチル−ベンズアミド誘導体
RU2259358C2 (ru) Производные цианоарил (или цианогетероарил)-карбонилпиперазинил-пиримидинов, способ их получения (варианты), фармацевтическая композиция и применение
FR2934996A1 (fr) Composes polysubstitues d'azetidines, leur preparation et leur application en therapeutique
HK40044347B (zh) 作为组蛋白去乙酰酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物
EP2411383A1 (fr) Derives de 3-alcoxy-4,5-diarylthiophene-2-carboxamide, leur preparation et leur application en therapeutique
HK1101283B (en) Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101283

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1101283

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090909

Termination date: 20180107

CF01 Termination of patent right due to non-payment of annual fee